Zebularine-induced reduction in VEGF secretion by HIF-1α degradation in oral squamous cell carcinoma

Molecular Medicine Reports

Volumn 1, Issue 4, 2008, Pages 465-471

  Suzuki, Maiko ^a   Shinohara, Fumiaki ^a   Rikiishi, Hidemi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Epigenetics; Hypoxia inducible factor 1 ; Oral squamous cell carcinoma; Vascular endothelial growth factor; Zebularine

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; VASCULOTROPIN A; VASCULOTROPIN C; ZEBULARINE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; EPIGENETICS; GENETIC REGULATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN STABILITY; SQUAMOUS CELL CARCINOMA;

EID: 69249127912     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.4.465     Document Type: Article

References (38)

1. Schliephake H: Prognostic relevance of molecular markers of oral cancer - a review. Int J Oral Maxillofac Surg 32: 233-245, 2003. (Pubitemid 36700729)
2. Shaw R: The epigenetics of oral cancer. Int J Oral Maxillofac Surg 35: 101-108, 2006.
3. Ha PK and Califano JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82, 2006.
4. Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M and Shibata T: Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132: 735-743, 2006. (Pubitemid 44337934)
5. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
6. Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3: 187-199, 2003.
7. Brueckner B and Lyko F: DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 25: 551-554, 2004. (Pubitemid 39371143)
8. Cheng JC, Yoo CB, Weisenberger DJ, et al: Preferential response of cancer cells to zebularine. Cancer Cell 6: 151-158, 2004.
9. Suzuki M, Shinohara F, Nishimura K, Echigo S and Rikiishi H: Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol 31: 1449-1456, 2007.
10. Hasina R and Lingen MW: Angiogenesis in oral cancer. J Dent Educ 65: 1282-1290, 2001.
11. Abdollahi A, Hlatky L and Huber PE: Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74, 2005.
12. Yamazaki Y and Morita T: Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10: 515-527, 2006. (Pubitemid 44885229)
13. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 2: 159-167, 2003.
14. Mukhopadhyay D and Datta K: Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 14: 123-130, 2004. (Pubitemid 38234754)
15. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K and Hamakawa H: Expression of vascular endothelial growth factor A, B, C and D in oral squamous cell carcinoma. Oral Oncol 40: 13-20, 2004. (Pubitemid 37510207)
16. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene reexpression in human lung and breast cancer cells. Cancer Res 64: 3137-3143, 2004. (Pubitemid 38581414)
17. Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684, 2003. (Pubitemid 36749216)
18. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
19. Sawair FA, Irwin CR, Gordon DJ, Leonard AG, Stephenson M and Napier SS: Invasive front grading: reliability and usefulness in the management of oral squamous cell carcinoma. J Oral Pathol Med 32: 1-9, 2003. (Pubitemid 36603927)
20. Johnstone S and Logan RM: The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol 42: 337-342, 2006.
21. Matsumura S, Oue N, Mitani Y, Kitadai Y and Yasui W: DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer. Int J Cancer 120: 1689-1695, 2007. (Pubitemid 46399355)
22. Miki K, Shimizu E, Yano S, Tani K and Sone S: Demethylation by 5-aza-2'-deoxycytidine (5-azaC) of p16INK4A gene results in down-regulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol Res 12: 335-342, 2001.
23. Blancher C, Moore JW, Robertson N and Harris AL: Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res 61: 7349-7355, 2001.
24. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000. (Pubitemid 30687077)
25. 2- independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25: 207-217, 2007.
26. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F and Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 277: 29936-29944, 2002.
27. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK and Lee HY: Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97: 1272-1286, 2005. (Pubitemid 41535368)
28. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000. (Pubitemid 30183422)
29. Alleman WG, Tabios RL, Chandramouli GV, et al: The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin Cancer Res 10: 7011-7021, 2004.
30. Ruesga MT, Acha-Sagredo A, Rodríguez MJ, et al: p16INK4a promoter hypermethylation in oral scrapings of oral squamous cell carcinoma risk patients. Cancer Lett 250: 140-145, 2007. (Pubitemid 46483851)
31. ink4a in oral squamous cell carcinoma lines by 5-aza-2′- deoxycytidine treatment induces a senescence-like state. Oncogene 17: 3445-3453, 1998.
32. Cheng JC, Weisenberger DJ, Gonzales FA, et al: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278, 2004.
33. Pal S, Datta K and Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61: 6952-6957, 2001. (Pubitemid 32896524)
34. INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. Int J Cancer 109: 483-490, 2004.
35. Claudio PP, Stiegler P, Howard CM, et al: RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res 61: 462-468, 2001. (Pubitemid 32128598)
36. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
37. Yang QC, Zeng BF, Shi ZM, et al: Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1α activity in human osteosarcoma. J Exp Clin Cancer Res 25: 593-599, 2006.
38. Kong X, Lin Z, Liang D, Fath D, Sang N and Caro J: Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α. Mol Cell Biol 26: 2019-2028, 2006. (Pubitemid 43346906)